A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

EXPERTS have warned over hundreds rushed to hospital after using weight loss jabs – as half a million Brits now use the injections. Nearly 400 users have been hospitalised with serious, ...

Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

In recent research, semaglutide showed a higher effectiveness for weight loss than older injections, with the potential for a 15% weight loss after 68 weeks in adults with a BMI of 30 or greater [1].

A woman who waited for four years on an NHS waiting list for weight-loss support has said she believes she could have avoided developing type 2 diabetes if she was given help sooner. Hannah Baker, 44, ...

Losing weight can feel like climbing a mountain with no clear path. The one-size-fits-all advice—like “eat less, move ...

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Weight loss drugs are seen as an easy option for dropping the pounds, but they are also expensive, and can have nasty side ...